Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion passed the Part 1 review (clinical design evaluation) for its Phase 3 Clinical Trial Application (CTA) for CT-P44, a Darzalex biosimilar candidate, from the European Medicines Agency (EMA).
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Major Matters Report Related to Investment Decisions
- Subject: Approval of Part 1 Review for Phase 3 Clinical Trial Application of CT-P44 (Darzalex Biosimilar) in Europe
- Reviewing Authority: European Medicines Agency (EMA)
- Application & Approval Dates (Local Time): Application Date 2024-11-27 / Part 1 Clearance Date 2025-03-31
- Confirmation Date: 2025-04-01 (Date confirmed via CTIS)
- Clinical Trial Details
- Study Title: A Double-Blind, Randomized, Active-Controlled, Parallel-Group Phase 3 Trial to Compare the Efficacy and Safety of Subcutaneous CT-P44 versus Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma
- Phase: Global Phase 3
- Target Indication: Refractory or Relapsed Multiple Myeloma
- Registration Number: EU CT number 2024-518588-36-00
- Patient Count: 486 subjects
- Duration: 2 years
- Purpose: To demonstrate biosimilarity between CT-P44 and the reference drug Darzalex in terms of efficacy and safety
- Regulatory Process & Investment Risks
- Under EU clinical trial regulations, this approval applies to Part 1 (assessment of clinical design and methodology). Final approval of Part 2 (assessment of trial sites and execution) is required to initiate the trial.
- Statistically, the probability of a clinical-stage drug candidate receiving final pharmaceutical authorization is approximately 10%. Commercialization plans may be altered or abandoned based on trial outcomes.
- Content of this disclosure will be utilized in upcoming press releases and IR materials.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Final Part 2 Approval for European Phase 3 Trial
This disclosure serves as official notification that Part 1 (clinical design evaluation) of the European Phase 3 CTA has been cleared. Tracking whether the final approval for Part 2 (assessment of trial sites and execution)—which is required to actually initiate clinical testing—is completed without issue is important for determining the feasibility of proceeding with trial execution. Relevant updates can be confirmed through subsequent major management disclosures, periodic reports, or official company IR materials.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
